Trial · NCT03200717
Adverse events460
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
121 to 140 of 460
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Aspartate aminotransferase increased | Investigations | Pazopanib- 2nd Line (On-Treatment) | 5 | 47 | |
| other | Aspartate aminotransferase increased | Investigations | Pazopanib- 3rd Line (On-Treatment) | 4 | 15 | |
| other | Aspartate aminotransferase increased | Investigations | Pazopanib- 2nd Line (Post-treatment Survival Follow-up) | 0 | ||
| other | Aspartate aminotransferase increased | Investigations | Pazopanib- 3rd Line (Post-treatment Survival Follow-up) | 0 | ||
| other | Blood alkaline phosphatase increased | Investigations | Pazopanib- 2nd Line (On-Treatment) | 2 | 47 | |
| other | Blood alkaline phosphatase increased | Investigations | Pazopanib- 3rd Line (On-Treatment) | 4 | 15 | |
| other | Blood alkaline phosphatase increased | Investigations | Pazopanib- 2nd Line (Post-treatment Survival Follow-up) | 0 | ||
| other | Blood alkaline phosphatase increased | Investigations | Pazopanib- 3rd Line (Post-treatment Survival Follow-up) | 0 | ||
| other | Blood bilirubin increased | Investigations | Pazopanib- 2nd Line (On-Treatment) | 3 | 47 | |
| other | Blood bilirubin increased | Investigations | Pazopanib- 3rd Line (On-Treatment) | 4 | 15 | |
| other | Blood bilirubin increased | Investigations | Pazopanib- 2nd Line (Post-treatment Survival Follow-up) | 0 | ||
| other | Blood bilirubin increased | Investigations | Pazopanib- 3rd Line (Post-treatment Survival Follow-up) | 0 | ||
| other | Blood creatine phosphokinase increased | Investigations | Pazopanib- 2nd Line (On-Treatment) | 0 | 47 | |
| other | Blood creatine phosphokinase increased | Investigations | Pazopanib- 3rd Line (On-Treatment) | 1 | 15 | |
| other | Blood creatine phosphokinase increased | Investigations | Pazopanib- 2nd Line (Post-treatment Survival Follow-up) | 0 | ||
| other | Blood creatine phosphokinase increased | Investigations | Pazopanib- 3rd Line (Post-treatment Survival Follow-up) | 0 | ||
| other | Blood creatinine increased | Investigations | Pazopanib- 2nd Line (On-Treatment) | 3 | 47 | |
| other | Blood creatinine increased | Investigations | Pazopanib- 3rd Line (On-Treatment) | 1 | 15 | |
| other | Blood creatinine increased | Investigations | Pazopanib- 2nd Line (Post-treatment Survival Follow-up) | 0 | ||
| other | Blood creatinine increased | Investigations | Pazopanib- 3rd Line (Post-treatment Survival Follow-up) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03200717/events?page=7